Skip to content
Screener

Spyre Therapeutics, Inc. SYRE Unrealized Losses on Investments (Before Tax)

Unrealized Losses on Investments (Before Tax) at other companies

Merck & Co. logo
Merck & Co.MRK
$0
Absci Corporation logo
Absci CorporationABSI
$125K+363%

Other financials

Income statement

See full
Revenue-
Operating income-$45.6M+14.8%
Net income-$69.0M-54.1%
EPS (diluted)-$0.74-23.3%

Balance sheet

See full
Cash & equivalents$97.2M+100%
Total debt$4.3M-9.6%
Total equity$670.8M+39.0%
Total assets$764.0M+34.1%

Cash flow

See full
Operating cash flow-$57.4M-40.0%
CapEx-
Free cash flow-$39.4M-26.8%

Valuation

See full
Market cap$9.29B+908%

Profitability

See full
Operating margin-39,428.9%-49,795pp
Net margin-52,939.7%-61,871pp
FCF margin-3,442.8%-3,807pp

Returns & leverage

See full
Return on equity-31.1%-10.7pp
Debt / equity0.1×+0.1×
Current ratio+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 8:00 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001636282-26-000050
Line itemAmortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Money market funds$95,448$95,448
Total cash equivalents$95,448$95,448
Marketable securities:
Commercial paper$164,635$1$(230)$164,406
Corporate bonds86,78817(149)86,656
U.S. government treasury securities257,224252(296)257,180
U.S. government agency securities136,40220(382)136,040
Total marketable securities$645,049$290$(1,057)$644,282

Item 1. Financial Statements (Unaudited).

FAQ

What is Spyre Therapeutics, Inc.'s unrealized losses on investments (before tax)?
Spyre Therapeutics, Inc. (SYRE) reported unrealized losses on investments (before tax) of $1.06M in Q1 2026.
How has Spyre Therapeutics, Inc.'s unrealized losses on investments (before tax) changed year-over-year?
Spyre Therapeutics, Inc.'s unrealized losses on investments (before tax) increased by 556.5% year-over-year, from $161K to $1.06M.
What is the long-term trend for Spyre Therapeutics, Inc.'s unrealized losses on investments (before tax)?
Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s unrealized losses on investments (before tax) has grown at a 55.3% compound annual growth rate (CAGR), from $31K to $116K.

Ask your AI about Spyre Therapeutics, Inc.'s unrealized losses on investments (before tax).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude